Marketresearchnews

Friday, 19 March 2021

Dissolvable Sutures Market Plying for Significant Growth During 2020 - 2027

Global dissolvable sutures market is expected to gain prominence over the forecast period (2018-2023). It is estimated that the global dissolvable sutures market is expected to grow at a CAGR ~5.2 % during the forecast period of 2018–2023.

Dissolvable sutures are stitches that doctors and surgeons, use to hold skin, internal organs, blood vessels, and all other tissues of the human body together, after the injury, incision, or surgery. These sutures have an anticipated advantage as they are broken down in the body tissue after a given period, and no foreign material left inside the patient's body.

The market growth is attributed to the increasing aging population, rising occurrence of chronic diseases, increasing healthcare expenditure, growing number of surgeries and burns, and increasing number of hospitals. According to the WHO, an estimate of tens of million people are injured or disabled worldwide every year in road accidents. Additionally, immense technological advancements in material science and increasing occurrences of musculoskeletal diseases are likely to boost the market growth during the forecast period.

Despite the drivers, the development of advanced wound care dressings and availability of alternatives such as surgical staplers and complications such as hemorrhage and leakage, especially in esophageal and colonic anastomosis are a few factors restraining the growth of the dissolvable sutures market. Furthermore, stringent government regulations and increasing preference for minimally invasive surgical procedures are the constraints limiting the market growth.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6081

Regional Analysis

The global dissolvable sutures market consists of four regions, namely, Americas, Europe, Asia Pacific, and the Middle East and Africa. North America holds the highest market share in the global dissolvable sutures market owing to the higher adoption of technologically advanced products for surgical procedures in the region, increase in the prevalence of various chronic diseases, and the development of the wound management sector. In addition, according to the Centers for Disease Control and Prevention, in 2015, an approximate 2.8 million people were hospitalized due to injuries in the United States.

Europe holds the second position in the global dissolvable sutures market. The availability of funds for research, increasing healthcare spending, huge patient population, and government support for research and development drive the European market. For instance, according to the National Statistics in 2015, the healthcare spending in the U.K. reached 271.6 USD billion in 2015 from 262.2 USD billion in 2014. Furthermore, the presence of developed countries such as Germany and the U.K. within the region is expected to fuel the market growth during the forecast period.

Asia Pacific is experiencing the fastest growth for the global dissolvable sutures market owing to the increasing prevalence of cardiac diseases, rising obese pool, and geriatric population. India and China dominate the market for dissolvable sutures in the Asia Pacific region. According to World Health Organization, over 1,000,000 people are moderately or severely burnt every year in India. In addition, availability of significant growth opportunities for prominent players due to improved healthcare infrastructure, the rise in healthcare awareness, surge in demand for better healthcare, and developing the medical tourism industry also fuel the growth of the market.

The Middle East and Africa holds the lowest share of the global market due to low development, lack of technical knowledge, and poor medical facilities, especially in the African region.

Regional Analysis

The Middle East and Africa holds the lowest share of the global market due to low development, lack of technical knowledge, and poor medical facilities, especially in the African region.

Segmentation

The global dissolvable sutures market is segmented on the basis of type, application, and end-user.

On the basis of type, the market is classified as natural dissolvable sutures and synthetic dissolvable sutures. Natural dissolvable sutures are further segmented as catgut plain sutures and catgut chromic sutures. Synthetic dissolvable sutures are further sub-segmented into polyglycolic acid sutures - coated and braided suture, polyglactin 910 sutures - coated and braided suture, poliglecaprone sutures - monofilament suture, and polydioxanone sutures - monofilament suture.

The global dissolvable sutures market on the basis of application is segmented into cardiovascular surgeries, general surgeries, gynecological surgeries, orthopedic surgeries, ophthalmic surgeries, and others.

On the basis of end-user, the global dissolvable sutures market is segmented into ambulatory surgical centers, hospitals, clinics, and others.

Global Dissolvable Sutures Key Players

Braun Melsungen AG, Boston Scientific Corporation, DemeTECH Corporation, NDOEVOLUTION LLC, Hu-Friedy Mfg. Co., LLC, Internacional Farmacéutica S.A. De C.V., Johnson & Johnson Services, Inc., Medline Industries, Inc., Medtronic, Péters Surgical, Roboz Surgical Instrument Co., Smith & Nephew, Surgical Specialties Corporation, and Sutures India Private Limited are prominent players in the global dissolvable sutures market.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/dissolvable-sutures-market-6081

Cruciate Ligament Diagnosis & treatment Market to Witness an Outstanding Growth by 2027

The cruciate ligament treatment includes numerous surgical techniques that involve reconstruction and replacement of the knee and related ligaments. The upsurge in obese population is considered as a chief factor emphasizing the growth of this market. Obesity in the aging population has been reported to directly increase the risk of degenerative bone disorders, such as osteoporosis and osteoarthritis, additionally resulting in target injury and fracture owing to the extra pressure exerted on joints. Later, increasing number of people who have osteoporosis is expected to generate demand for the market.

However, the lack of availability of skilled professionals and the high cost of treatment procedures may hinder the growth of the market during the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6080

Many prominent players in the market have incorporated into acquisitions, mergers, and continuous launches of quality systems to hold the market position. The firms are focusing on mergers and acquisitions to enhance their product portfolio. For instance, the acquisition of Cayenne Medical by Zimmer Biomet was involved in reconstruction solutions and advanced soft tissue repair for knee, shoulder, and extremities. Besides, companies are involving into geographic expansions to cater to the untargeted population for tissue repair and surgeries.

Regional Analysis

The global cruciate ligament diagnosis and treatment market consists of four regions, namely, Americas, Europe, Asia Pacific, and the Middle East and Africa.

The American region holds the major share of the global cruciate ligament diagnosis and treatment market, owing to the existing well-established healthcare system, increasing prevalence of degenerative bone disorder cases, and technological advancements. Sports such as soccer, football, and skiing have been reported to be high-risk sports that can cause injury to the ACL when compared to other sports activities. For instance, due to increasing occurrences of ACL injuries, nearly 100,000 ACL reconstructions are performed each year as per a report published by PubMed.

Europe holds the second position in the global cruciate ligament diagnosis and treatment market. It is expected that the government support towards research and development expenditure and rising prevalence of chronic bone diseases are likely to drive the European cruciate ligament diagnosis and treatment market.

The Asia Pacific cruciate ligament diagnosis and treatment market consist of countries, namely, China, Japan, the Republic of Korea, India, Australia, and the Rest of Asia Pacific. Japan is the largest market for cruciate ligament diagnosis and treatment due to an increase in the prevalence of cancer and demand for cruciate ligament diagnosis and treatment techniques. In China, factors responsible for the market growth are rising geriatric population with osteoporosis diseases and availability of low-cost diagnostic and treatment options.

The Middle East and Africa holds the lowest share of the global market due to low development, lack of technical knowledge, and poor medical facilities.

Segmentation

The global cruciate ligament diagnosis and treatment market is segmented on the basis of type, injury type, product, diagnosis, treatment, and end-user.

Based on type, the global cruciate ligament diagnosis and treatment market is classified as Posterior Cruciate Ligament (PCL) and Anterior Cruciate Ligament (ACL).

The segments for injury type for the global cruciate ligament diagnosis and treatment market are classified as grade I, grade II, and grade III.

On the basis of product, the global cruciate ligament diagnosis and treatment market is classified as cemented implants, cement-less implants, partial implants, and revision implants.

Based on indication, the global cruciate ligament diagnosis and treatment market is classified as osteoarthritis, rheumatoid arthritis, trauma, and others.

The diagnosis segment for the global cruciate ligament diagnosis and treatment market is classified as imaging and others. The imaging segment is further classified as abdominal x-ray, Magnetic Resonance Imaging (MRI), ultrasound, laparoscopy, angiography, and others.

Based on treatment, the global cruciate ligament diagnosis and treatment market is classified as surgery, therapies, devices, and others. Surgery can be further sub-divided into arthroscopy, Anterior Cruciate Ligament (ACL) reconstruction, and others. The therapies include rehabilitation and physical therapies. The devices include elastic bandages and others.

On the basis of end-user, the global cruciate ligament diagnosis and treatment market is classified as hospitals, orthopedic clinics, Ambulatory Surgical Center (ASC), and others.

Global Cruciate Ligament Diagnosis & Treatment Key Players

Stryker Corporation (U.S.), Arthrex, Inc. (U.S.), Zimmer Biomet (U.S.), DePuy Synthes, Inc. (U.S.), CONMED Corporation (U.S.), Smith & Nephew plc. (U.S.), DJO Global Inc. (U.S.), Breg, Inc. (U.S.), Bauerfeind AG (Germany), Össur hf. (Iceland), DeRoyal Industries, Inc. (U.S.), BSN Medical GmbH (Germany), 3M Company (U.S.), Otto Bock Healthcare GmbH (Germany), THUASNE SA (France), medi GmbH & Co. KG (Germany), DeRoyal Industries Inc. (U.S.), Corin Group (UK), United Orthopedic Corporation (Taiwan), Exactech Inc. (U.S.), Japan Medical Dynamic Marketing (Japan), Tornier Inc. (U.S.), and others are some prominent players in this market.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/cruciate-ligament-diagnosis-treatment-6080

Pain Management Market Plying for Significant Growth During 2020 - 2027

The global pain management market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the pain management market is expected to register a CAGR of 6.0% during the forecast period of 2018–2023.

Pain is considered as a clinical, social, and economic burden in communities around the world, as chronic pain is associated with various health conditions. The increasing prevalence of pain pushes the demand for better diagnosis and treatments.

Notably, the market is expected to expand in the near future due to increasing technological advancements. The increasing occurrences of chronic pain conditions are continuously motivating marketers to come up with more technologically advanced products. For instance, a new noninvasive neuromodulation device, Stimpod NMS460 was introduced by the Xavant Technology to treat the chronic intractable pain. The device has received an FDA approval on August 01, 2017.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5975

According to a study published in the Current Pain and Headache Reports Journal in 2016, it was found that Peripheral Nerve Stimulation (PNS) is a widely accepted treatment procedure for chronic pain. The StimRouter neuromodulation system by Bioness, Inc is a PNS technology-based device specifically designed to treat chronic pain. The device received the FDA approval in 2015.

Various other factors such as increasing geriatric population, improved reimbursement policies in developed countries, the increasing prevalence of cancer pain, improving regulatory framework, growing research funding, unmet medical needs, rising competition among market players, and increasing government assistance are continuously contributing to the growth of the global pain management market.

Despite these drivers, there are some issues associated with the pain management market. The high cost associated with the technology, lack of skilled or trained physicians, and poor healthcare system in low and middle-income countries may hamper the growth of the market.

Regional Analysis

The Americas dominates the pain management market owing to the increasing prevalence of chronic pain, well-developed technology, high healthcare expenditure, and the presence of leading players. According to a study published in the Drug and Alcohol Dependence Journal in 2017, more than 100 million adult Americans are living with chronic pain. Chronic low back pain and headaches are the most commonly diagnosed conditions. It is also stated that such conditions are more prevalent in women than men, i.e., 34.3% in women, and 26.7% in men in the United States.

Europe holds the second position in the pain management market. It is expected that the increasing contribution towards research and development and increasing competition among marketers are likely to drive the European pain management market.

Asia Pacific is the fastest growing pain management market owing to a huge patient pool, increasing demand for treatments, and increasing healthcare expenditure. As per the data suggested by the Australian Institute of Health and Welfare during 2015 to 2016, the total health expenditure was nearly USD 170.4 billion, i.e., 3.6% higher than the expenditure of 2014 to 2015.

The Middle East and Africa holds the lowest share of the global pain management market due to low development, lack of technical knowledge, and poor medical facilities.

Segmentation

The global pain management market is segmented on the basis of type of pain management devices, type of pain management drugs, indication, mode of purchase, and end-user.

On the basis of type of pain management devices, the market is classified as neurostimulation devices, analgesic infusion pumps, and ablation devices. Neurostimulation devices are further segmented into Transcutaneous Electrical Nerve Stimulation (TENS) devices and Spinal Cord Stimulation (SCS) devices. Ablation devices are further segmented into RF ablation devices and cryoablation devices.

On the basis of type of pain management drugs, the market is classified as Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), anticonvulsants, anesthetics, opioids, antimigraine agents, antidepressants, and others. The opioids segment is further classified as oxycodones, hydrocodones, tramadol, morphine, codeine, fentanyl, meperidine, methadone, and others.

On the basis of indication, the market is classified as neuropathic pain, cancer pain, facial pain and migraine, musculoskeletal pain, fibromyalgia, chronic back pain, arthritic pain, migraine, post-operative pain, and others.

On the basis of the mode of purchase, the market is classified as over the counter and prescription-based.

On the basis of end-user, the market is classified as hospitals and clinics, pharmaceutical companies, medical device companies, research and academic institutes, and others.

Key Players

Some of the key players in the global pain management market are Abbott Laboratories, Abbvie, Allergan, Astellas Pharma, AstraZeneca plc, Bayer AG, Codman And Shurtleff, Inc, DJO Global LLC, Eli Lilly & Company, Endo Health Solutions, F. Hoffmann-La Roche Ltd, Forest Laboratories, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Mallinckrodt plc, Medtronic PLC, ST. Jude Medical, Inc., Boston Scientific Corporation, Pfizer Inc., Halyard Health, Inc., Smiths Medical, B. Braun Melsungen AG, Neurotech Na, Inc., Becton, Dickinson and Company, Nevro Corp., Merck & Co. Inc., Novartis AG, Purdue Pharma LP, Sanofi, Stryker Corporation, Teva Pharmaceuticals, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/pain-management-market-5975

Global Neurocutaneous Disorder Market to Record an Exponential CAGR by 2027

The neurocutaneous syndrome is a group of neurologic disorders of brain, spine, and the peripheral nervous system. These diseases are lifelong conditions that may induce a tumor growth inside the skin, organs, skeletal bones, brain, and spinal cord.

These disorders are usually genetic and arise due to abnormal cell development at the embryo stage. The result is characterized by the development of tumors in various parts of the body. Even though some can be diagnosed at birth, most of them do not display symptoms until late. These syndromes cannot be cured, but various treatments can assist to manage the symptoms and any health concern. Lately, significant advances have been made by the use of DNA testing to confirm these syndromes in some people.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5937

The three most common types of neurocutaneous syndromes are Tuberous sclerosis (TS), Neurofibromatosis (NF): Type I, Type II, and schwannomatosis, and Sturge-Weber disease.

Tuberous sclerosis (TS) is a non-cancerous growth that occurs in organs such as brain, eyes, kidneys, heart, lungs, bones, and skin. There is a 50% chance of children to develop TS if the parent is affected by it. Moreover, the Sturge-Weber Syndrome (SWS) causes malformations relating to the face, eye, and brain. It is estimated that about 1 in 20,000 to 50,000 live births may be affected with the Sturge-Weber syndrome.

Increasing government initiatives for ensuring the early diagnosis is supposed to be a significant driver of the market. Moreover, many guidelines are issued by government organizations to promote awareness related to effective prevention measures, globally. All these factors are expected to contribute to the market growth throughout the forecast period. Moreover, concerns regarding the safety of reprocessed instruments and stringent regulations for sterilization equipment manufacturers and service providers are factors hampering the market growth.

Global market for neurocutaneous disorders is expected to have a CAGR of approximately 6.5% during 2017 to 2023.

Segmentation

The global neurocutaneous disorder market has been segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of type, the global neurocutaneous disorder market can be segmented into Tuberous Sclerosis (TS), Neurofibromatosis (NF), Sturge-weber syndrome, Ataxia-Telangiectasia (A-T), Von Hippel-Lindau disease (VHL), and others.

Neurofibromatosis (NF) is further divided into Neurofibromatosis type 1 (NF1), Neurofibromatosis type 2 (NF2), and schwannomatosis. The Sturge-weber syndrome is divided into type-1, type-2, and type-3.

On the basis of diagnosis, the global neurocutaneous disorder market can be segmented into skull radiography, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, Electroencephalogram (EEG), genetic tests (blood testing), biopsy, and others

On the basis of treatment, the global neurocutaneous disorder market can be segmented into medication, laser therapy, surgical procedures, and others.

Medication is further divided into antiepileptic, beta-antagonist eye drops, carbonic anhydrase inhibitors, adrenergic eye drops, miotic eye drops, and others. Surgical procedures are further divided into focal cortical resection, hemispherectomy, corpus callosotomy, trabeculectomy, filtration surgery, cyclocryotherapy, Vagal Nerve Stimulation (VNS), and others.

On the basis of end-user, the global neurocutaneous disorder market is segmented into hospitals and clinics, diagnostic centers, and others.

Regional Analysis

The global neurocutaneous disorder market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas region accounted for the largest market share of the global neurocutaneous disorder market owing to the increasing awareness about genetic disorders along with the growing number of drug and medical service providers. As per the National Institute of Neurological Disorders and Stroke (NINDS) in 2017, Neurofibromatosis Type 1 (NF1) occurs in about 1 in 3,000 to 4,000 births in the U.S. This condition is a chromosomal disorder which is inherited from a parent. Moreover, Neurofibromatosis Type 2 (NF2) occurs less frequently, affecting about 1 in 25,000 births in the U.S.

The European neurocutaneous disorder market is the second largest market followed by Asia Pacific. The Asia Pacific region is expected to exhibit the fastest growth throughout the forecast period owing to the exceptional healthcare standards and infrastructure, rising healthcare expenditure, and growing presence of outsourcing organizations across this region. Moreover, the presence of various government organizations dedicated to improving the standards for neurocutaneous disorders is among the significant factors contributing towards the growth of the Asia Pacific region.

The Middle Eastern region is expected to grow at a steady pace owing to factors such as the extensive development of the healthcare infrastructure and increasing R&D activities in the healthcare sector.

Key Players

Some of the key players in the global neurocutaneous disorder market are Valeant Pharmaceuticals International, Inc. (U.S.), Allergan (U.S.), Syneron Medical Ltd (U.S.), Medtronic Plc (U.S.), Cutera, Inc. (U.S.), St Jude Medical, Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Abbott Laboratories Inc. (U.S.), UCB S.A. (Belgium), Sanofi SA (France), Shire Plc (Ireland), F. Hoffmann-La Roche AG (Switzerland), Aleva Neurotherapeutics SA (Switzerland), Johnson & Johnson (U.S.), and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/neurocutaneous-disorder-market-5937

Paroxysmal Supraventricular Tachycardia (PSVT) Market to Witness an Outstanding Growth by 2027

Supraventricular tachycardia is a condition where there is a rapid increase in the heart rate that is caused by electrical impulses originating above the heart. Paroxysmal supraventricular tachycardia, also known as PSVT, is a condition wherein the patient shows an irregularity in heart beating. People suffering from this disorder experience sudden and unexpected occurrence of rapid heart rate that start and stop without warning. A normal heart beats between 60 to 100 beats per minute, but the heart rate of a person suffering from paroxysmal supraventricular tachycardia during an episode may exceed 150–200 beats per minute.

The prevalence of Paroxysmal Supraventricular Tachycardia (PSVT) is unknown but is projected to be around several cases per thousand persons. But, a recent study conducted by Milestone Pharmaceuticals suggested that about 1.7 million patients in the U.S. were suffering from paroxysmal supraventricular tachycardia since the last five years.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5918

The most common types of arrhythmias include atrial fibrillation, atrial flutter, sick sinus syndrome, sinus tachycardia, supraventricular tachycardia, ventricular tachycardia, ventricular fibrillation, and premature ventricular contractions. Moreover, some arrhythmias may lead to more serious medical problems such as sudden stroke or cardiac arrest.

The global Paroxysmal Supraventricular Tachycardia (PSVT) market is expected to register a CAGR of approximately 6.50% during the forecast period, 2017–2023.

Regional Analysis

The global Paroxysmal Supraventricular Tachycardia (PSVT) market consists of regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas region dominates the global Paroxysmal Supraventricular Tachycardia (PSVT) market. Besides, the occurrence of Supraventricular Tachycardia (SVT) is approximately 35 cases per 100,000 patients with a prevalence of 2.25 cases per 1,000 among the American population.

The European market is expected to hold the second largest market share for the global Paroxysmal Supraventricular Tachycardia (PSVT) market over the forecast period. Norway and Sweden are among the key countries within the European Paroxysmal Supraventricular Tachycardia (PSVT) market. The subtypes atrial tachycardia and Atrioventricular Reentrant Tachycardia (AVRT) account for approximately 10% and 30% of the SVT cases, respectively.

The Asia Pacific region is emerging at the highest growth rate than any other region globally. In the region, countries such as China and Japan are exhibiting high occurrence rate for heart disorders. The increasing demand for diagnostic outpatient surgeries has fueled the growth of the Paroxysmal Supraventricular Tachycardia (PSVT) market in Asia Pacific. In India, the increasing healthcare services, availability of low cost of labor, increasing number of hospitals, and better access to technology drive the growth of this market.

Segmentation

The Paroxysmal Supraventricular Tachycardia (PSVT) market is segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of type, the global Paroxysmal Supraventricular Tachycardia (PSVT) market is segmented into AV Nodal Re-Entrant Tachycardia (AVNRT), AV Reciprocating Tachycardia (AVRT), Paroxysmal atrial tachycardia (PAT), and Wolff-Parkinson-White Syndrome (WPW).

On the basis of diagnosis, the global Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into Electrophysiology Study (EPS), stress test, cardiac catheterization, coronary angiography, Electrocardiogram (ECG), echocardiogram, Holter monitor, event monitor, implantable monitor, lab tests, and others. Lab tests are further classified into blood test, urine test, and others.

On the basis of treatment, the global Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into physical maneuvers, medications, catheter ablation, pacemaker, and cardioversion. Medication can be segmented into calcium channel blockers, beta blockers, antiarrhythmic medication, and others. Calcium channel blockers are further divided into diltiazem, verapamil, and others. Antiarrhythmic medication is divided into sotalol, amiodarone, amiodarone, flecainide, propafenone, and adenosine.

On the basis of end-user, the global Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into hospitals and clinics, diagnostic centers, medical research centers, and others.

Key Players

Some of the key players in the global Paroxysmal Supraventricular Tachycardia (PSVT) market are GlaxoSmithKline PLC (U.K.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), AstraZeneca PLC (U.K.), Teva pharmaceutical industries (Israel), Sanofi SA (France), Medtronic, Inc. (U.S.), Glenmark Pharmaceuticals (U.S.), St. Jude Medical, Inc. (U.S.), BIOTRONIK SE & Co. KG (U.S.), GE Healthcare (U.S.), Boston Scientific Corporation (U.S.), Abbott Laboratories Inc. (U.S.), (Alcon) Novartis (U.S.), Siemens AG (Germany), Koninklijke Philips N.V. (U.S.), and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/paroxysmal-supraventricular-tachycardia-market-5918

Obesity Treatment Market Projected to Witness Vigorous Expansion by 2027

Obesity is a disorder characterized by an excessive amount of body fat. The medical condition not only generates cosmetic concerns but is also related to various diseases and health problems, including heart diseases, diabetes, and others. A variety of treatment options are available in the market for obesity treatment, which ranges from medications to surgeries. Growing obese population and increasing acceptance of bariatric surgeries are expected to be the major drivers for the market growth during the forecast period. The Monash University stated that Australia recorded a burgeoning number of bariatric surgeries in 2015, accounting for approximately 15,000 procedures within the region. Moreover, the increasing demand for minimally invasive surgeries, rising awareness, and favorable reimbursement policies are expected to boost the market growth during the forecast period. However, factors such as high cost of surgery followed by the risks of infection and anesthesia allergy and low healthcare expenditure in the middle and low-income countries are estimated to restrain the market growth during the forecast period. According to a study published in the Obesity Surgery Journal in 2017, the mean total cost for bariatric procedures such as gastric bypass or adjustable gastric banding was estimated to be around USD 14,389.

The Global Obesity Treatment Market is expected to grow at an approximate CAGR of 16.7% during forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5872

Segmentation

The global obesity treatment market is segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of types, the market is segmented into inactivity obesity, food obesity, anxiety obesity, venous obesity, atherogenic obesity, and gluten obesity. On the basis of diagnosis, the market is categorized into blood tests, physical examination, and others. The blood tests segment is sub-segmented into cholesterol test, liver function test, thyroid test, and others. The physical examination segment is sub-segmented into heart rate measurement, blood pressure measurement, and others. On the basis of treatment, the market is segmented into medication, surgery, lifestyle changes, and others. The medication segment is sub-segmented into orlistat, lorcaserin, phentermine and topiramate, liraglutide, and others. The surgery segment is sub-segmented into gastric bypass surgery, Laparoscopic Adjustable Gastric Banding (LAGB), gastric sleeve, biliopancreatic diversion, gastric sleeve, and others. On the basis of end-users, the market is segmented into hospitals, clinics, pharmacies, and others.

Regional Analysis

The Americas dominates the global obesity treatment market. The increasing obese population, the presence of a well-developed healthcare sector, and presence of developed economies such as the U.S. and Canada are the drivers for the market growth within the region. Additionally, increasing healthcare expenditures and presence of market players such as Medtronic, Mediflex Surgical Products, Johnson & Johnson Services, Inc., and others within the Americas boost the regional growth of the market. Europe is second in the global obesity treatment market owing to the availability of funds for research, growing obese population, and increasing adoption of bariatric surgeries within the region. Asia Pacific is estimated to be the fastest growing region. This can be attributed to the increasing obese population, presence of developing economies, and a growing healthcare sector within the region. On the other hand, the Middle East and Africa holds the least share in the global obesity treatment market. The presence of poor economies and stringent government policies especially within the Africa region restrict the regional market growth.

Key Players

Some of the key players for the global obesity treatment market are VIVUS, Inc. (U.S.), Arena Pharmaceuticals, Inc. (U.S.), F. Hoffmann-La Roche, Ltd. (Switzerland), Novo Nordisk A/S (Denmark), Orexigen Therapeutics, Inc. (U.S.), Allergan (Republic of Ireland), Cousin Biotech (France), EnteroMedics, Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Medtronic (U.S.), USGI Medical, Inc. (U.S.), Mediflex Surgical Products (U.S.), Covidien plc (Republic of Ireland), Olympus Corporation (Japan), and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/obesity-treatment-market-5872

Global Delirium Market to Observe Strong Development by 2027

Delirium is a neurological (nervous system) condition and a serious disturbance in mental abilities that causes mental confusion and emotional disruption. Delirium can be caused due to various factors such as older age, exposure to certain medications, alcohol abuse, surgery or other medical procedures, factors such as exposure to toxic or infectious agents, physical trauma, diet, and behavioral and occupational factors.

The global delirium market is majorly driven by the increasing prevalence of neurological disorders and increasing older population leading to rise in patient population. Additionally, increasing government initiatives, increasing programs to create awareness, and market players offering advanced products are likely to drive the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5850

According to the United Nations, in 2017 approximately over 962 million population was aged over 60 and above globally. United Nations has also estimated that by 2050, the number of older population is likely to reach 425 million. This rising aging population is likely to propel the growth of global delirium market. Lack of awareness regarding the treatment is likely to hamper the growth of the market.

The Global Delirium Market is expected to grow at a CAGR of 6% during the forecast period.

Regional Analysis

The Americas dominates the global delirium market owing to the increasing aging population and increasing rate of neurological conditions. Additionally, the increasing government initiatives and awareness programs are likely to enhance the growth of delirium in the North American region. Similarly, increasing government healthcare costs, along with the increasing awareness among population regarding mental health is expected to drive the growth of the delirium market in North America. For instance, iDelirium, a federation of 3 delirium societies (American Delirium Society, European Delirium Society, and Australasian Delirium Association) has launched various awareness programs across the country to spread awareness regarding delirium and its effects.

Europe accounts for the second largest market due to increasing aging mass and increasing neurological disorders. Additionally, the improving government funding and increasing healthcare infrastructure along with the increasing demand for technologically advanced treatment are driving the growth of delirium market in Europe. For instance, Eurostat estimated that over 19.2% of the population in Europe was aged 65 and above. This rising older population is likely to drive the growth of the delirium market.

Asia Pacific is the fastest growing market for delirium whose growth is attributed to the increasing population which in turn increases the overall patient population and rising population affected by post-surgical disorders. India and China are the primary contributors to the market growth due to the rising demand for advanced and newer treatments and rising development of healthcare infrastructure in these regions.

On the other hand, the Middle East and Africa is expected to witness a restricted growth due to limited access and affordability of the healthcare system and lack of awareness among individuals. In the Middle East, the growth of the market is driven by the growing awareness regarding neurological disorders and expanding healthcare scenario.

Segmentation

The global delirium market is segmented on the basis of type, treatment, diagnosis, and end-user.

On the basis of type, the market is segmented into hyperactive, hypoactive, and mixed.

On the basis of diagnosis, the market is segmented into laboratory tests, imaging tests, and physical examination. On the basis of laboratory tests, it is further sub-segmented into blood tests and urine tests. On the basis of imaging tests, it is further sub-segmented into brain-imaging tests.

On the basis of treatment, the market is segmented into antipsychotics and supportive care. On the basis of treatment, antipsychotics is further sub-segmented into risperidone, olanzapine, and quetiapine.

On the basis of end-user, the market is segmented into specialty centers, hospitals, and research centers.

Key Players

Some of the key players in the delirium market are Dr. Franz Kohler Chemie GmbH, Fraser Health, Gaia BioPharma Ltd., Novartis AG, Pfizer, Inc., Regenstrief Institute, Inc., and Air Liquide Sante International, among others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/delirium-market-5850